pemetrexed
Showing 26 - 50 of 527
Lung Cancer Trial in Nashville (Pemetrexed, Gemcitabine)
Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)
Recruiting
- Non Small Cell Lung Cancer
- Osimertinib
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Aug 18, 2022
NSCLC Metastatic Trial in Salt Lake City (Durvalumab, Pemetrexed, Carboplatin)
Recruiting
- Non-Small Cell Lung Cancer Metastatic
- Durvalumab
- +2 more
-
Salt Lake City, UtahHuntsman Cancer Institute at University of Utah
Mar 1, 2022
NSCLC Trial in Tianjin (Tislelizumab, Pemetrexed, Bevacizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Tislelizumab
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 11, 2022
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma Trial in Augusta (Cabozantinib,
Recruiting
- Non Small Cell Lung Cancer
- +3 more
- Cabozantinib
- Pemetrexed
-
Augusta, GeorgiaAugusta University Georgia Cancer Center
Mar 6, 2022
Metastatic Non-squamous Non Small Cell Lung Cancer Trial in Worldwide (Cosibelimab, Cisplatin, Carboplatin)
Active, not recruiting
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Cosibelimab
- +6 more
-
Vitória, Brazil
- +21 more
Aug 17, 2022
Lung Adenocarcinoma, Cryotherapy Effect Trial in Bordeaux (Cryoablation, Pembrolizumab, Pemetrexed)
Recruiting
- Lung Adenocarcinoma
- Cryotherapy Effect
- Cryoablation
- +3 more
-
Bordeaux, Gironde, FranceInstitut Bergonié
Oct 29, 2021
Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation Trial in Japan (Pembrolizumab, Lenvatinib, Carboplatin)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- EGFR Activating Mutation
- Pembrolizumab
- +3 more
-
Urayasu, Chiba, Japan
- +9 more
Jul 19, 2022
NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)
Terminated
- Carcinoma, Non-Small-Cell Lung
- capmatinib
- +4 more
-
Kashiwa, Chiba, Japan
- +3 more
Jan 31, 2023
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
Advanced Cancers Trial in Houston (Crizotinib (Xalkori), Pazopanib, Pemetrexed)
Terminated
- Advanced Cancers
- Crizotinib (Xalkori)
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 3, 2021
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular
Recruiting
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant
- +6 more
- Avelumab
- Pemetrexed
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2021
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa
Recruiting
- Lung Non-Small Cell Carcinoma
- +4 more
- Carboplatin
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Aug 16, 2022
NSCLC Trial in China (Atezolizumab, Placebo, Bevacizumab)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Atezolizumab
- +5 more
-
Beijing City, China
- +22 more
Dec 7, 2022
Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)
Not yet recruiting
- Stage II-IIIB(N2) Non-small Cell Lung Cancer
- TQB2450
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Oct 26, 2023
Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)
Not yet recruiting
- Lung Cancer, Non-squamous, Non-small Cell
- zongertinib
- +4 more
- (no location specified)
Nov 22, 2023
Mesothelioma, Malignant Trial in China (Nivolumab, Ipilimumab, Pemetrexed)
Recruiting
- Mesothelioma, Malignant
- Nivolumab
- +4 more
-
Beijing, Beijing, China
- +25 more
Jan 17, 2023
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC Trial in Worldwide (Atezolizumab, Bevacizumab, Carboplatin)
Active, not recruiting
- EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
- Atezolizumab
- +4 more
-
Großhansdorf, Germany
- +17 more
Jan 12, 2023
NSCLC Trial in Seoul (Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab)
Recruiting
- Non-small Cell Lung Cancer
- Atezolizumab(Tecentriq)
- +5 more
-
Seoul, Gangnamgu, Korea, Republic ofSamsung Medical Center
Dec 27, 2021
Metastatic NSCLC, Stage III NSCLC Trial (inupadenant, Placebo, Carboplatin)
Recruiting
- Metastatic NSCLC
- Stage III NSCLC
- inupadenant
- +3 more
-
Fayetteville, Arkansas
- +16 more
Jan 25, 2023
Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation Trial (Pembrolizumab, Pemetrexed,
Withdrawn
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab
- +4 more
- (no location specified)
Mar 14, 2022
Nonsquamous NSCLC Trial in Yichang (Sintilimab, Docetaxel, Pemetrexed)
Recruiting
- Nonsquamous Non-Small Cell Lung Cancer
- Sintilimab
- +2 more
-
Yichang, Hubei, ChinaDepartment of Medical Oncology, Central Hospital of Yichang City
Nov 5, 2021